A presentation to: Meeting name Date

Slides:



Advertisements
Similar presentations
Medical Retina and Macular Diseases
Advertisements

Age-Related Macular Degeneration
ARAVIND EYE CARE SYSTEM Aravind Eye Hospital & Postgraduate Institute of Ophthalmology ARAVIND EYE CARE SYSTEM Aravind Eye Hospital & Postgraduate Institute.
Luu CD, Dimitrov PN, Robman L, et al. Role of flicker perimetry in predicting onset of late-stage age-related macular degeneration. Arch Ophthalmol. 2012;130(6):
Phase IIIb Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration PIER Study Year 1 Regillo CD,
The Diabetic Retinopathy Clinical Research Network Green or Yellow Laser for Diabetic Macular Edema Sponsored by the National Eye Institute, National Institutes.
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: AMD in the Age-Related Eye Disease Study Chew EY, Clemons TE, Agrón E, et al;
Blindness or low vision effects more than 3 million Americans 40 years and older, and this number is projected to reach 5.5 million by In addition.
Date of download: 5/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Randomized, Placebo-Controlled, Clinical Trial.
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Single-Nucleotide Polymorphisms and Age-Related Macular Degeneration Maguire MG,
Macular Degeneration Chaminda Unantenne RN,MS,MSN  
The Diabetic Retinopathy Clinical Research Network
A Review of Ranibizumab Clinical Trial Data in Exudative Age-Related Macular Degeneration and How to Translate It into Daily Practice Ophthalmologica 2011;225:112–119.
Optical coherence tomography in the diagnosis and managment
The Diabetic Retinopathy Clinical Research Network
Vignette and Discussion Questions
A presentation to: Meeting name Date
The Diabetic Retinopathy Clinical Research Network
Macular Degeneration.
Age Related macular degeneratIon-ClassIfIcatIon
Copyright © 2005 American Medical Association. All rights reserved.
From: Optimizing the Anti-VEGF Treatment Strategy for Neovascular Age-Related Macular Degeneration: From Clinical Trials to Real-Life Requirements Trans.
AGE-RELATED MACULAR DEGENERATION (AMD)
Copyright © 2006 American Medical Association. All rights reserved.
A presentation to: Meeting name Date
A presentation to: Meeting name Date
Current Treatments and Updates of the Big 4
A presentation to: Meeting name Date
A presentation to: Meeting name Date
DESIGN ISSUES OF A NON-INFERIORITY TRIAL
JAMA Ophthalmology Journal Club Slides: Validity of the Age-Related Eye Disease Study Grading Scale Vitale S, Clemons TE, Agrón E, et al; Age-Related Eye.
Association between risk-of-bias assessments and results of randomized trials in Cochrane reviews: the ROBES study Jelena Savović1, Becky Turner2, David.
Geographic Atrophy in a Clinical Trial Environment
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
The Diabetic Retinopathy Clinical Research Network
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
AMD update Macular research.
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
Copyright © 2016 Elsevier Inc. All rights reserved.
A presentation to: Meeting name Date
Diabetic Retinopathy Clinical Research Network
DRCR Retina Network Treatment for Center-Involved DME in Eyes with Good Visual Acuity (Protocol V)
Colin Tan, Alex Tham, Tiakumzuk Sangtam, Kah-Guan Au Eong
Presentation transcript:

A presentation to: Meeting name Date Laser treatment of drusen to prevent progression to advanced age-related macular degeneration Gianni Virgili, Manuele Michelessi, Maurizio B Parodi, Daniela Bacherini, Jennifer R Evans Issue 10, 2015 A presentation to: Meeting name Date

Table of Contents 01 Background 02 Types of studies 03 Key results 04 Tables (Risk of Bias/Forest Plots) 05 Conclusions 06 Acknowledgements

01: Background Drusen are yellowish deposits under the retina Drusen contribute to a higher risk of developing age- related macular degeneration Laser photocoagulation of drusen can lead to drusen disappearance and may prevent visual loss Objective: To examine the effectiveness and adverse effects of laser photocoagulation of drusen in AMD

02: Types of studies Participants 11 randomized controlled trials, 3580 eyes of 2159 participants Interventions Laser treatment of drusen in AMD VERSUS No intervention or sham treatment

03: Key results “Photocoagulation did not reduce the development of CNV at two years' follow-up…” OR 1.07, 95% CI 0.79 to 1.46; 2159 participants “…photocoagulation led to drusen reduction but was not shown to limit loss of 3 or more lines of visual acuity.” Drusen reduction – OR 9.16, 95% CI 6.28 to 13.4 Visual Acuity – OR 0.99, 95% CI 0.81 to 1.22

04: Tables

04: Tables Development of choroidal neovascularization

05: Conclusions “The trials included in this review confirm the clinical observation that laser photocoagulation of drusen leads to their disappearance. However, treatment does not result in a reduction in the risk of developing CNV, and was not shown to limit the occurrence of geographic atrophy or visual acuity loss.”

06: Acknowledgements Cochrane Eyes and Vision US Satellite, funded by the National Eye Institute, National Institutes of Health Cochrane Eyes and Vision Editorial Base, funded by the UK National Health Service Research and Development Programme Gianni Virgili, Manuele Michelessi, Maurizio B Parodi, Daniela Bacherini, Jennifer R Evans Review citation Virgili G, Michelessi M, Parodi MB, Bacherini D, Evans JR. Laser treatment of drusen to prevent progression to advanced age-related macular degeneration. Cochrane Database of Systematic Reviews 2015, Issue 10. Art. No.: CD006537. DOI: 10.1002/14651858.CD006537.pub3